Literature DB >> 20509010

New therapeutic approaches to resistant hypertension.

Markus P Schlaich1, Henry Krum, Murray D Esler.   

Abstract

Resistant hypertension is a common and growing clinical problem characterized by failure to achieve target blood pressure levels despite adequate use of at least three antihypertensive agents. Although numerous safe and effective pharmacologic therapies are available to treat elevated blood pressure, novel therapeutic approaches are warranted to improve the management and prognosis of patients with resistant hypertension. In this context, several lines of research have generated promising results based on both novel pharmacologic and device-based approaches that may more effectively treat resistant hypertension and its adverse consequences in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20509010     DOI: 10.1007/s11906-010-0119-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  A limited renal injury may cause a permanent form of neurogenic hypertension.

Authors:  S Ye; M Gamburd; P Mozayeni; M Koss; V M Campese
Journal:  Am J Hypertens       Date:  1998-06       Impact factor: 2.689

2.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

Review 3.  Vasopeptidase inhibitors.

Authors:  M A Weber
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

4.  Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity.

Authors:  Shaohua Ye; Huiqin Zhong; Vijay Yanamadala; Vito M Campese
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

5.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

6.  Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.

Authors:  Roumen Nakov; Egon Pfarr; Siegfried Eberle
Journal:  Am J Hypertens       Date:  2002-07       Impact factor: 2.689

7.  Prolonged activation of the baroreflex produces sustained hypotension.

Authors:  Thomas E Lohmeier; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

Authors:  Morris J Brown; John Coltart; Kulasiri Gunewardena; James M Ritter; Timothy R Auton; James F Glover
Journal:  Clin Sci (Lond)       Date:  2004-08       Impact factor: 6.124

10.  Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology.

Authors:  Luis A Sanchez; Karl Illig; Mark Levy; Gregory Trachiotis; Charles Shanley; Eric Irwin; Jeffrey Jim; Martin Rossing; Robert Kieval
Journal:  Ann Vasc Surg       Date:  2009-12-29       Impact factor: 1.466

View more
  3 in total

1.  Postmenopausal hypertension: role of the sympathetic nervous system in an animal model.

Authors:  Rodrigo O Maranon; Roberta Lima; Mohammed Mathbout; Jussara M do Carmo; John E Hall; Richard J Roman; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-12-31       Impact factor: 3.619

2.  Resistant hypertension workup and approach to treatment.

Authors:  Anastasios Makris; Maria Seferou; Dimitris P Papadopoulos
Journal:  Int J Hypertens       Date:  2010-12-26       Impact factor: 2.420

Review 3.  Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

Authors:  Thomas Unger; Ludovit Paulis; Domenic A Sica
Journal:  Eur Heart J       Date:  2011-09-27       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.